

1 **Ad hoc laboratory-based surveillance of SARS-CoV-2 by real-time RT-PCR using**
2 **minipools of RNA prepared from routine respiratory samples**

3

4 Anna M. Eis-Hübinger¹, Mario Hönemann², Jürgen J. Wenzel³, Annemarie Berger⁴, Marek
5 Widra⁴, Barbara Schmidt³, Souhaib Aldabbagh¹, Benjamin Marx¹, Hendrik Streeck¹, Sandra
6 Ciesek⁴, Uwe. G. Liebert², Daniela Huzly⁵, Hartmut Hengel⁵, Marcus Panning⁵

7

8 1 Institute of Virology, University of Bonn, Faculty of Medicine, Bonn, Germany

9 2 Institute of Virology, University of Leipzig, Leipzig, Germany

10 3 Institute of Clinical Microbiology and Hygiene, Regensburg University Hospital,

11 Regensburg, Germany

12 4 Institute of Medical Virology, University Hospital, Goethe University Frankfurt am Main,

13 Frankfurt, Germany

14 5 Institute of Virology, University Medical Center Freiburg, Faculty of Medicine, University

15 of Freiburg, Freiburg, Germany.

16

17 **Running Title:** SARS-CoV-2 laboratory-based surveillance

18

19 Address for correspondence: Marcus Panning, Institute of Virology, University Medical

20 Centre Freiburg, Hermann-Herder-Str. 11, 79104 Freiburg, Germany; email:

21 marcus.panning@uniklinik-freiburg.de, Fon: +49 761 203 6610, Fax: +49 761 203 6603

22

23 **Keywords:** SARS-CoV-2, RT-PCR, minipools, surveillance, laboratory

24 **Abstract (50 words)**

25 We report a laboratory-based surveillance for SARS-CoV-2 using minipools of respiratory
26 samples submitted for routine diagnostics. We tested a total of 70 minipools resembling 700
27 samples shortly before the upsurge of cases in Germany. We identified one SARS-CoV-2
28 positive patient. Our approach proved its concept, is easily adaptable and resource-saving.

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44 **Text (word count 1,158)**

45 As of 11 March 2020, WHO declared COVID-19 a pandemic (1). Early case detection
46 is crucial to contain the pandemic and symptom-based case definitions have been set up in
47 many countries worldwide. However, there is evidence that transmission chains can be
48 initiated by asymptomatic cases or only mildly diseased COVID-19 patients (2). These cases
49 will be missed by currently recommended symptom-based case definitions and may lead to
50 unrecognized local spread, which has been seen in Italy, Iran and more recently in parts of the
51 US. One of the biggest challenges and unresolved issues for public health is the rapid
52 identification of SARS-CoV-2 transmission chains within the general population and
53 ultimately in hospitals.

54 Here we propose an *ad hoc* laboratory-based surveillance approach for SARS-CoV-2 which
55 might help to identify unrecognized spread in an efficient, resource-saving and cost effective
56 manner. It is based upon minipool (MP) testing of nucleic acid preparations of respiratory
57 samples submitted to laboratories for routine diagnostics.

58 **The study**

59 The workflow comprises individual nucleic acid (NA) extraction of respiratory
60 samples, pooling of extracted NA samples in batches of 10 and SARS-CoV-2 specific real-
61 time RT-PCR. In a first step, we analyzed the impact of minipool (MP) testing in batches of
62 10 samples per pool. Nucleic acid was extracted from 200 µl respiratory specimen
63 (pharyngeal swabs in viral transport medium, sputum, broncho-alveolar lavage fluid) using
64 the MinElute Virus kit (Qiagen, Hilden, Germany) on the QIAcube system as recommended.
65 Elution was done in a volume of 100 µl. For setting up MP, 5 µl of each individual NA
66 preparation was combined in pools of 10 (dilution factor of 10). We retrieved 40 left-over NA
67 preparations of respiratory samples representing a variety of non-SARS-CoV-2 viruses from

68 our local biobank in Freiburg and set up MP. We tested four MP using the same RT-PCR as
69 for individual patient testing as described (3). We were able to detect all viral pathogens
70 which tested positive in individual RT-PCR (Table 1). To exclude possible unspecific
71 reactions of the MP procedure these MP were also tested using the SARS-CoV-2 specific
72 real-time RT-PCR as described below and no unspecific reactions were observed.

73 To determine the analytical sensitivity of the MP approach, we used *in vitro*-
74 transcribed RNA standards for the E gene obtained by the European virus archive global
75 (EVAg), <https://www.european-virus-archive.com>, and the SARS-CoV-2 E gene RT-PCR
76 assay as described (4). RT-PCR was done on an ABI 7500 instrument (Applied Biosystems,
77 Weiterstadt, Germany). We spiked different *in vitro*-transcribed RNA concentrations in stored
78 NA preparations of respiratory samples from 2019 and established MP. Replicate testing was
79 done to determine the limit of detection (LOD) as described (4). The LOD for the MP
80 approach was 48 copies per reaction (95% confidence interval: 33 – 184) (Figure 1). We used
81 NA preparations from three actual SARS-CoV-2 cases in Freiburg (containing 4×10^4
82 copies/ml; 3.2×10^7 copies/ml; 1.6×10^7 copies/ml, respectively) and set up three MP each
83 containing one SARS-CoV-2 positive NA preparation and retested these samples. Except for
84 the MP containing the low concentrated sample both other MP tested positive.

85 Finally, we prospectively analyzed 42 MP comprising 420 samples using the SARS-
86 CoV-2 E gene assay. We used all available NA samples which had been sent for routine
87 diagnostics to the Institute of Virology in Freiburg excluding samples with a specific request
88 for SARS-CoV-2 diagnostics from 17.02.2020 to 10.03.2020 (Figure 2). One out of 42 MP
89 tested positive. The MP was resolved and individual testing confirmed SARS-CoV-2
90 infection in one individual patient.

91 We distributed the workflow within an informal network of 5 German laboratories
92 (Table 2). All sites are tertiary care centers with a total of 1.600 (site A), 1.300 (site B), 1.400

93 (site C), 840 beds (site D), and 1.500 (site E), respectively. Invited laboratories rapidly
94 adopted the MP screening strategy and a total of 70 MP were tested from 17.02.2020-
95 10.03.2020 (Figure 2). At sites B to E all MP tested SARS-CoV-2 negative. Of note, site B
96 provided another 4 MP artificially spiked with SARS-CoV-2 positive NA samples from actual
97 cases to further validate the procedure. The Ct-values of SARS-CoV-2 RT-PCR in individual
98 patient samples were 26, 26, 15, and 35, respectively. All artificially spiked MP tested SARS-
99 CoV-2 positive and Ct-values were 29, 29, 18, and 38 indicating a dilution factor of 10 as
100 expected.

101 **Conclusions**

102 We report a diagnostic workflow for the laboratory-based surveillance of SARS-CoV-
103 2 in a rapid and cost effective manner. Shortly after the identification of SARS-CoV-2
104 specific real-time RT-PCR protocols were set up and have been distributed worldwide (4, 5).
105 The availability of rapid and reliable diagnostics for early case detection is instrumental in an
106 outbreak scenario (6). From a public health perspective an easy to establish and cost effective
107 laboratory-based screening strategy may assist in rapid case detection and ultimately in a
108 better understanding of this epidemic (7). Technically, this can be done in parallel using
109 samples from routine diagnostics which are subsequently tested for SARS-CoV-2 RNA (8).
110 However, with the circulation of influenza cases across Europe merging with the upsurge of
111 SARS-CoV-2 many laboratories may lack the capacity and resources to perform additional
112 single patient sample testing for SARS-CoV-2. In addition, a shortage of PCR reagents has
113 become an issue of concern as huge numbers of additional SARS-CoV-2 molecular tests are
114 performed globally in a relatively short period of time. To minimize work load, resources and
115 costs a pooling approach of nucleic acid extractions might be considered. We used the assay
116 described by Corman et al. and were able to demonstrate an almost exactly 10-fold higher
117 LOD which is due to MP related dilution factor of 10 (4). Data from China showed SARS-

118 CoV-2 RNA concentrations in the range of $1,5 \times 10^4$ to $1,5 \times 10^7$ copies per milliliter giving rise
119 to the notion that the MP procedure will be sensitive enough for most clinical samples (9).

120 However, at the moment there is a lack of comprehensive information on viral RNA
121 concentrations in mildly diseased or asymptomatic cases. Critically, we were not able to
122 detect one low concentrated samples diluted into a MP, which was close to the LOD of the
123 pooling procedure.

124 Networks are paramount for an efficient response to emerging infections and we aimed to
125 provide an easy to implement workflow (4, 10). We set up an informal network and were able
126 to test a total of 70 MP covering different geographic regions of Germany. In perspective, this
127 approach can be set up rather easily e. g. by public health laboratories, can be done on a daily
128 basis and at reduced costs compared to individual patient testing. It could allow for
129 longitudinally monitoring the effectiveness of contact reduction measures at the population
130 level and early detection of epidemic waves.

131 In light of an evolving SARS-CoV-2 epidemic and the possibility of unrecognized spread
132 within the population we propose a rapid and straightforward screening strategy for SARS-
133 CoV-2. This approach proved its principle and might assist public health laboratories in
134 Europe and elsewhere to rapidly detect SARS-CoV-2 cases which might otherwise remain
135 undetected.

136

137

138

139

140

141

142

143 **Acknowledgement**

144 We are grateful to Claudia Ehret, Monika Häffner, Verena Schillinger and the team in
145 Freiburg and the entire molecular diagnostic teams in Bonn, Frankfurt, Leipzig, and
146 Regensburg for expert technical assistance.

147

148 **Ethical considerations**

149 All samples have been submitted for routine patient care and diagnostics. Ethical approval for
150 this study was not required since all activities are according to legal provisions defined by the
151 German Infection Protection Act (IfSG). Written informed consent has been obtained by each
152 patient. All data used in the current study was anonymized prior to being obtained by the
153 authors.

154

155 **Data availability**

156 The data that support the findings of this study are available from the corresponding
157 author upon reasonable request.

158

159

160

161

162

163

164

165

166

167

168

169 **References**

- 170 1. World Health Organization. Director-General's opening remarks at the media briefing
171 on COVID-19 - 11 March 2020.
- 172 2. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented
173 infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). *Science*.
174 2020.
- 175 3. Huzly D, Korn K, Bierbaum S, Eberle B, Falcone V, Knoll A, et al. Influenza A virus
176 drift variants reduced the detection sensitivity of a commercial multiplex nucleic acid
177 amplification assay in the season 2014/15. *Arch Virol*. 2016;161(9):2417-23.
- 178 4. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection
179 of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill*. 2020;25(3).
- 180 5. Reusken C, Broberg EK, Haagmans B, Meijer A, Corman VM, Papa A, et al.
181 Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories
182 in 30 EU/EEA countries, January 2020. *Euro Surveill*. 2020;25(6).
- 183 6. Johnson HC, Gossner CM, Colzani E, Kinsman J, Alexakis L, Beauté J, et al. Potential
184 scenarios for the progression of a COVID-19 epidemic in the European Union and the
185 European Economic Area, March 2020. *Euro Surveill*. 2020;25(9).
- 186 7. Lipsitch M, Swerdlow DL, Finelli L. Defining the Epidemiology of Covid-19 -
187 Studies Needed. *N Engl J Med*. 2020.
- 188 8. Bordi L, Nicastrì E, Scorzolini L, Di Caro A, Capobianchi MR, Castillette C, et al.
189 Differential diagnosis of illness in patients under investigation for the novel coronavirus
190 (SARS-CoV-2), Italy, February 2020. *Euro Surveill*. 2020;25(8).
- 191 9. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load
192 in Upper Respiratory Specimens of Infected Patients. *N Engl J Med*. 2020.
- 193 10. Panning M, Eickmann M, Landt O, Monazahian M, Olschlager S, Baumgarte S, et al.
194 Detection of influenza A(H1N1)v virus by real-time RT-PCR. *Euro Surveill*. 2009;14(36).

195 **Table 1:** Detection of respiratory viruses in samples using individual RT-PCR and in four
 196 minipools of 10 individual samples (A1 – A4), Freiburg, Germany, December 2019.

Patient sample	Pathogen	Ct-value (Individual patient analysis)	Minipool	Pathogen	Ct-value (Minipool analysis)
1	Influenza B virus	29	A1	Influenza B virus	25
2	negative			negative	
3	negative			negative	
4	negative			negative	
5	negative			negative	
6	negative			negative	
7	negative			negative	
8	negative			negative	
9	negative			negative	
10	negative			negative	
11	negative		A2	negative	
12	RSV	25		RSV	29
13	negative			negative	
14	negative			negative	
15	Influenza A virus	33		Influenza A virus	34
16	negative			negative	
17	negative			negative	
18	negative			negative	
19	negative			negative	
20	negative			negative	
21	negative		A3	negative	
22	Rhinovirus, HMPV	24, 25		Rhinovirus, HMPV	31, 30
23	negative			negative	
24	Adenovirus	25		Adenovirus	29
25	negative			negative	
26	negative			negative	
27	negative			negative	
28	RSV	32		RSV	35
29	Negative			negative	
30	negative			negative	
31	negative		A4	negative	
32	RSV	34		RSV	>35
33	Influenza A virus	37		Influenza A virus	33
34	negative			negative	
35	Influenza A virus	32		Influenza A virus	29
36	negative			negative	
37	negative			negative	
38	negative			negative	
39	negative			negative	
40	HMPV	32		HMPV	34

197 **Table 2:** Number of minipools tested for SARS-CoV-2 RNA at five different sites, Germany,
198 February – March 2020 (n=60).

Laboratory site	Minipools tested (n=)	Individual samples (n=)	SARS-CoV-2 RT-PCR positive patients (n=)
A (Freiburg)	42	420	1
B (Bonn)	6	100	0
C (Leipzig)	9	90	0
D (Regensburg)	8	80	0
E (Frankfurt)	5	70	0
Total	70	700	0

199

200

201

202

203

204

205

206

207

208

209

210

211


212

213

214 **Legends to the figures**


215 **Figure 1:** Probit analysis of SARS-CoV-2 RNA detection rate (y axes) in relation to viral

216 RNA concentration at different copy numbers per reaction (x axes).



217

218 **Figure 2:** Number of minipools tested by date at five sites in Germany, February-March



219

220 *: First SARS-CoV-2 RNA positive minipool detected